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Letters to the Editor
Is There an Optimal
Hematocrit Value for Cardiac Patients?
The significance of anemia in congestive heart failure (CHF) has
only recently received attention, as evidenced by two state-of-the-
art papers published over the last several months (1,2). Anemia is
more common in CHF than could be accounted for by age or the
degree of renal dysfunction (2). Moderate to severe anemia can
contribute to the development or worsening of CHF. Conversely,
CHF can lead to moderate anemia (2). Recent reports have largely
resolved the question: Is anemia a cause or a consequence of CHF?
(3). Erythropoietin, which has a long history in the management of
anemia complicating chronic renal failure, is being used for
treatment of anemia in CHF (4–6).
Besides the potential risks of worsening hypertension and
increased thrombosis as pointed out by Felker et al. (1), anemia
correction in CHF may have other adverse effects. High hemato-
crit has been reported to be associated with a higher rate of Q-wave
myocardial infarction (MI) after coronary artery bypass grafting
(7). That a high hematocrit value was associated with an increased
risk for MI has actually been known for a long time (8). As a
matter of fact, George Burch (9–14), who wrote extensively on the
subject since the early 1960s, advocated bloodletting in patients
with coronary artery disease with a high hematocrit value (13,14).
It might be appropriate to quote what Burch wrote in 1979 (14):
“It is well known that a high hematocrit is associated with
high viscosity and that a highly viscous fluid requires more
work of the pump to circulate it than does a less viscous
liquid. Furthermore, the flow of highly viscous fluid is
reduced, even with all else being equal. Nevertheless, phy-
sicians fail to bleed patients with active coronary disease and
myocardial ischemia, whose hematocrit is high and whose
blood viscosity is increased. It has been shown that blood-
letting in patients with ischemic heart disease definitely
improved the clinical state of these patients when their
hematocrit was reduced to average normal levels.”
Therefore, as Felker et al. (1) cautioned, one must balance the risk
of correcting the anemia in CHF against the risks of such
treatment. What the optimal hematocrit value should be for
patients with coronary artery disease or CHF has to await the
results of controlled studies on a large number of patients.
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Further Aspects of Anemia,
Heart Failure, and Erythropoietin
A routine laboratory hemoglobin measurement reflects “hemoglo-
bin concentration.” This approximates the total-body circulating
hemoglobin (TBH) to plasma volume (PV) ratio, but provides no
absolute quantitative information about either TBH or PV. Ane-
mia arises when the TBH:PV ratio falls. This occurs with either
decreased TBH or increased PV. This distinction is important: in a
recent study, 46% of anemic patients with heart failure had a normal
total red cell volume, with anemia attributable to excess PV (1).
In their review, Felker et al. (2) raise several issues concerning
anemia and heart failure that warrant further consideration. They
adopt the term “true anemia” to describe a decrease in TBH (2).
This begs the question: is a reduced hemoglobin concentration any
truer if it arises from decreased TBH rather than increased PV?
Undoubtedly not, and the term “true anemia” should probably be
avoided as it is imprecise. Felker et al. also indicate that “anemia
results in decreased oxygen-carrying capacity” (2). Again, this
statement is imprecise. It is a decrease in TBH that results in
decreased oxygen-carrying capacity.
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